MALVERN, Pa., July 20, 2016 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, is pleased to announce that the District Court in the District of Massachusetts has entered a July 14, 2016 Consent Judgment permanently enjoining and restraining InfoBionic, Inc. (“InfoBionic”) from “making, using, offering to sell, or selling within the United States or importing into the United States” any of its “First-Generation” MoMe® Kardia system and from “engaging in any other act of infringement” by its “First-Generation” system as defined under federal patent law.
BioTelemetry is pleased with this initial result, and has pending patent infringement claims against InfoBionic’s “Second-Generation” MoMe® Kardia system as well as claims for misappropriation of BioTelemetry’s trade secrets. BioTelemetry has asserted that such trade secrets were misappropriated, in part, by one or more former BioTelemetry executives and employees who joined InfoBionic and were involved in the development of its MoMe® Kardia system.
BioTelemetry is represented by a litigation team from Sidley Austin LLP’s New York office.
BioTelemetry, Inc., formerly known as CardioNet, Inc., is the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care. The company currently provides cardiac monitoring services, original equipment manufacturing with a primary focus on cardiac monitoring devices and centralized cardiac core laboratory services. More information can be found at www.biotelinc.com.
Cautionary Statement Regarding Forward-Looking Statements
This document includes certain forward-looking statements within the meaning of the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "expect," "anticipate," "estimate," "intend," "plan," "believe," "promises" and other words and terms of similar meaning. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including important factors that could delay, divert, or change any of these expectations, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, our ability to defend our patent portfolio and obtain favorable results, effects of changes in health care legislation, effectiveness of our cost savings initiatives, relationships with our government and commercial payors, changes to insurance coverage and reimbursement levels for our products, the success of our sales and marketing initiatives, our ability to attract and retain talented executive management and sales personnel, our ability to identify acquisition candidates, acquire them on attractive terms and integrate their operations into our business, the commercialization of new products, market factors, internal research and development initiatives, partnered research and development initiatives, competitive product development, changes in governmental regulations and legislation, the continued consolidation of payors, acceptance of our new products and services, patent protection, adverse regulatory action, litigation success, our ability to successfully create a new holding company structure and to anticipate the benefits of such structure. For further details and a discussion of these and other risks and uncertainties, please see our public filings with the Securities and Exchange Commission, including our latest periodic reports on Form 10-K and 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
CONTACT: Contact: BioTelemetry, Inc. Heather C. Getz Investor Relations 800-908-7103 firstname.lastname@example.org